中国血液透析行业发展调研报告

Research report on the development of China's hemodialysis

目的调查中国内地地区血液透析行业的发展现状,为国家相关医疗政策的制订提供参考。方法采用问卷调查、文献检索、现场摸底等方法,全面调研中国内地地区(不含香港地区、澳门地区和台湾地区)31个省、自治区、直辖市的血液透析行业发展状况,包括维持性血液透析人数、血液透析中心数量及性质、血液透析产业制造情况等。结果截至2022年底,我国内地地区共有维持性血液透析患者850809人。共有透析中心7399家,其中26.1%属于三级医院,61.6%属于二级医院,8.5%属于一级医院或未定级医院,3.8%未分类;公立医院占84.9%,民营医院占15.1%。截至2022年底,在我国内地地区注册的血液净化设备生产企业共30家,其中进口企业12家,国产企业18家,以德国费森尤斯医药用品股份公司(费森尤斯)的市场占有率最高,为38%;透析器生产企业48家,其中进口企业17家,国产企业31家,山东威高血液净化制品股份有限公司(威高)的市场占有率最高,为30%;灌流器生产企业14家,其中进口企业3家,国产企业11家,珠海健帆生物科技集团股份有限公司(健帆)的市场占有率最高,为74%;血液透析管路生产企业35家,其中进口企业5家,国产企业30家,威高的市场占有率最高,为23%;血液透析穿刺针生产企业23家,尼普洛(上海)有限公司(尼普洛)的市场占有率最高,为40%;血液透析液/粉生产企业39家;血液透析用水处理设备生产企业31家,其中进口企业5家,国产企业26家。结论我国维持性血液透析患者数量庞大,血液透析中心相对不足,且主要集中在二级和三级公立医院,血液透析行业市场发展潜力巨大。而透析设备、透析器等血液透析的核心产品仍主要依赖进口,国内企业需提高技术水平和市场竞争力,早日实现国产品牌的崛起。

Objective To investigate the current situation of hemodialysis in China' Mainland and provide references for the future national medical policies.Methods The number of maintenance hemodialysis patients and hemodialysis centers,as well as the manufacturing of hemodialysis industry were investigated in 31 provinces in China' Mainland using the methods of questionnaire survey,on-site survey and literature review.Results By the end of 2022,there were a total of 850,809 maintenance hemodialysis patients and 7,399 dialysis centers in China' Mainland.26.1%of the hemodialysis centers belonged to tertiary hospitals,61.6%belonged to secondary hospitals,and 8.5%belonged to primary hospitals or unclassified hospitals and 3.8%were not categorized.Public hospitals account for 84.9%of the hemodialysis centers,while private hospitals account for 15.1%.There were 30 registered blood purification equipment manufacturing companies in China' Mainland,including 12 foreign companies and 18 domestic companies,with Fresenius having the highest market share of 38%.There were 48 dialyzer manufacturing companies,including 17 foreign companies and 31 domestic companies,with Weigao having the highest market share of 30%.There were 14 manufacturers of hemoperfusion cartridge,including 3 foreign companies and 11 domestic companies,with Jianfan having the highest market share of 74%.There were 35 manufacturers of hemodialysis tubing,including 5 foreign companies and 30 domestic companies,with Weigao having the highest market share of 23%.There were 23 manufacturers of fistula puncture needles,with Nipro having the highest market share of 40%.There were 39 manufacturers of dialysate or hemodialysis dry powder.There were 31 manufacturers of water disposal equipment for hemodialysis,including 5 foreign companies and 26 domestic companies.Conclusion There are a large number of maintenance hemodialysis patients in China' Mainland.However,the hemodialysis centers are relatively insufficient and mainly distributed in secondary and tertiary hospitals,indicating enormous potential for the future development of hemodialysis.On the other hand,the core products of hemodialysis,such as dialysis equipment and dialyzers,rely mainly on foreign companies.Domestic companies should improve technology to be more competitive in the future.